Literature DB >> 32826617

Disparities in Access to Medications for Opioid Use Disorder in the Veterans Health Administration.

Andrea K Finlay1, Alex H S Harris, Christine Timko, Mengfei Yu, David Smelson, Matthew Stimmel, Ingrid A Binswanger.   

Abstract

OBJECTIVES: A variety of patients - including women, older, racial/ethnic minority, rural, homeless, and justice-involved patients - are vulnerable to experiencing poor healthcare access and quality, such as lower quality substance use disorder treatment, than other populations. The current study examined receipt of medications for opioid use disorder by vulnerable populations within Veterans Health Administration (VHA) facilities to determine whether there are patient and facility factors that are associated with disparities in care.
METHODS: Using national VHA clinical/administrative data from Fiscal Year 2017, we calculated receipt of medications for opioid use disorder using the American Society for Addiction Medicine quality measure specifications. A mixed-effects logistic regression model tested whether patient vulnerability (ie, women, older age, racial/ethnic minority, rural residence, homeless, and justice-involved) and facility (eg, regional location, availability of a methadone clinic) characteristics were associated with medication receipt.
RESULTS: Among the 53,568 veterans at VHA facilities diagnosed with opioid use disorder in Fiscal Year 2017, vulnerable populations - including women, older, Black, rural, homeless, and justice-involved veterans - had lower odds of receiving medications for opioid use disorder than their nonvulnerable counterparts. Veterans had higher odds of receiving medications at facilities with a higher proportion of patients with opioid use disorder, but lower odds of receiving medications at facilities in the Southern region compared to the Northeast region of the United States.
CONCLUSIONS: Quality improvement efforts targeted at vulnerable populations are needed at the VHA to ensure these groups receive the same quality of substance use disorder treatment as other veterans.

Entities:  

Mesh:

Year:  2021        PMID: 32826617      PMCID: PMC7889740          DOI: 10.1097/ADM.0000000000000719

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   4.647


  35 in total

Review 1.  Prevention and Treatment of Opioid Misuse and Addiction: A Review.

Authors:  Nora D Volkow; Emily B Jones; Emily B Einstein; Eric M Wargo
Journal:  JAMA Psychiatry       Date:  2019-02-01       Impact factor: 21.596

Review 2.  The National Institute on Aging Health Disparities Research Framework.

Authors:  Carl V Hill; Eliseo J Pérez-Stable; Norman A Anderson; Marie A Bernard
Journal:  Ethn Dis       Date:  2015-08-07       Impact factor: 1.847

3.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

4.  Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters.

Authors:  Tyler L Quest; Joseph O Merrill; John Roll; Andrew J Saxon; Roger A Rosenblatt
Journal:  J Opioid Manag       Date:  2012 Jan-Feb

5.  Identifying women veterans with unhealthy alcohol use using gender-tailored screening.

Authors:  Katherine J Hoggatt; Tracy Simpson; Catherine A Schweizer; Karen Drexler; Elizabeth M Yano
Journal:  Am J Addict       Date:  2018-03

6.  Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.

Authors:  Elizabeth M Oliva; Alex H S Harris; Jodie A Trafton; Adam J Gordon
Journal:  Drug Alcohol Depend       Date:  2011-11-23       Impact factor: 4.492

Review 7.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

8.  Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations.

Authors:  Hannah K Knudsen; Paul M Roman
Journal:  Sociol Focus       Date:  2009

9.  Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science.

Authors:  Andrea K Finlay; Ingrid A Binswanger; Christine Timko; David Smelson; Matthew A Stimmel; Mengfei Yu; Tom Bowe; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2018-10-02

10.  Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals.

Authors:  Gerod Hall; Charles J Neighbors; Jude Iheoma; Sarah Dauber; Merribeth Adams; Robert Culleton; Fred Muench; Suzanne Borys; Rebecca McDonald; Jon Morgenstern
Journal:  J Subst Abuse Treat       Date:  2013-12-02
View more
  9 in total

1.  Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.

Authors:  Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

2.  Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.

Authors:  Lewei Allison Lin; Lan Zhang; Hyungjin Myra Kim; Madeline C Frost
Journal:  Am J Psychiatry       Date:  2022-07-28       Impact factor: 19.242

3.  Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder.

Authors:  Madeline C Frost; Julie E Richards; John R Blosnich; Eric J Hawkins; Judith I Tsui; E Jennifer Edelman; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2022-06-03       Impact factor: 4.852

4.  WVSUD-PACT: a Primary-Care-Based Substance Use Disorder Team for Women Veterans.

Authors:  Sara Spinella; Nicole McCune; Rebecca McCarthy; Maria El-Tahch; Jennifer George; Mary Dorritie; Alyssa Ford; Kira Posteraro; Deborah DiNardo
Journal:  J Gen Intern Med       Date:  2022-08-30       Impact factor: 6.473

5.  Effects of Medicaid expansion on alcohol and opioid treatment admissions in U.S. racial/ethnic groups.

Authors:  Nina Mulia; Camillia K Lui; Kara M K Bensley; Meenakshi S Subbaraman
Journal:  Drug Alcohol Depend       Date:  2021-12-24       Impact factor: 4.852

6.  Legal System Involvement and Opioid-Related Overdose Mortality in U.S. Department of Veterans Affairs Patients.

Authors:  Andrea K Finlay; Kristen M Palframan; Matthew Stimmel; John F McCarthy
Journal:  Am J Prev Med       Date:  2021-09-12       Impact factor: 5.043

7.  Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study.

Authors:  Erica Morse; Ingrid A Binswanger; Emmeline Taylor; Caroline Gray; Matthew Stimmel; Christine Timko; Alex H S Harris; David Smelson; Andrea K Finlay
Journal:  J Subst Abuse Treat       Date:  2021-03-04

8.  A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.

Authors:  Emmeline N Taylor; Christine Timko; Ingrid A Binswanger; Alex H S Harris; Matthew Stimmel; David Smelson; Andrea K Finlay
Journal:  Subst Abus       Date:  2021-09-29       Impact factor: 3.984

9.  The acceptability and feasibility of screening, brief intervention, and referral to treatment for pain management among new England veterans with chronic pain: A pilot study.

Authors:  John J Sellinger; Steve Martino; Christina Lazar; Kristin Mattocks; Kenneth Rando; Kristin Serowik; Karen Ablondi; Brenda Fenton; Kathryn Gilstad-Hayden; Bradley Brummett; Paul E Holtzheimer; Diana Higgins; Thomas E Reznik; Alicia M Semiatin; Todd Stapley; Tu Ngo; Marc I Rosen
Journal:  Pain Pract       Date:  2021-06-26       Impact factor: 3.079

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.